Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 51 (21), 6902-15

Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-cell Lymphoma 2 Proteins

Affiliations

Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-cell Lymphoma 2 Proteins

Cheol-Min Park et al. J Med Chem.

Abstract

Overexpression of prosurvival proteins such as Bcl-2 and Bcl-X L has been correlated with tumorigenesis and resistance to chemotherapy, and thus, the development of antagonists of these proteins may provide a novel means for the treatment of cancer. We recently described the discovery of 1 (ABT-737), which binds Bcl-2, Bcl-X L, and Bcl-w with high affinity, shows robust antitumor activity in murine tumor xenograft models, but is not orally bioavailable. Herein, we report that targeted modifications at three key positions of 1 resulted in a 20-fold improvement in the pharmacokinetic/pharmacodynamic relationship (PK/PD) between oral exposure (AUC) and in vitro efficacy in human tumor cell lines (EC 50). The resulting compound, 2 (ABT-263), is orally efficacious in an established xenograft model of human small cell lung cancer, inducing complete tumor regressions in all animals. Compound 2 is currently in multiple phase 1 clinical trials in patients with small cell lung cancer and hematological malignancies.

Similar articles

See all similar articles

Cited by 65 PubMed Central articles

See all "Cited by" articles

Substances

LinkOut - more resources

Feedback